ArticleInternational journal of clinical oncology2015

Clinical features and risk factors of panitumumab-induced interstitial lung disease: a postmarketing all-case surveillance study.

Masahiro Osawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.